Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity

J Neural Transm (Vienna). 2015 Jun;122(6):779-88. doi: 10.1007/s00702-014-1334-8. Epub 2014 Dec 13.

Abstract

Nitrative stress is a key component of the pathogenic process in Parkinson's disease (PD), but the relative roles of constitutive neuronal nitric oxide synthase (n-NOS) and inducible nitric oxide synthase (i-NOS) in glial cells remain unresolved. We have investigated the effects of a range of concentrations of the selective n-NOS inhibitor ARR17477, and the selective i-NOS inhibitor 1400W, on MPP(+)-induced cell death in foetal ventral mesencephalic (VM) dopaminergic cultures. MPP(+) induced a loss of TH-positive neurones accompanied by an increase in immunoreactivity for GFAP and OX-6 as markers of astrocytes and activated microglia, respectively, and induced i-NOS immunoreactivity. Unexpectedly, MPP(+) treatment did not induce 3-NT immunoreactivity in the cultures. ARR17477 and 1400W alone had no effect on the number of TH-positive cells or on the number of GFAP or OX-6 positive cells. ARR17477 did not prevent the MPP(+)-induced decrease in TH-positive neurones and had no effect on the increased number of GFAP- and OX-6-positive cells. By contrast, 1400W caused a concentration-dependent preservation of TH-positive neurones in the presence of MPP(+). It also significantly reduced the number of OX-6-immunoreactive cells and there was a small reduction in GFAP immunoreactivity. The results suggest a major role for i-NOS-mediated nitrative stress in microglia in MPP(+)-induced dopaminergic cell death and this may have important implications for developing neuroprotective strategies for PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amidines / pharmacology
  • Animals
  • Antibodies, Monoclonal / metabolism
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Benzylamines / pharmacology
  • Cell Count
  • Cells, Cultured
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / enzymology
  • Dopaminergic Neurons / pathology
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Glial Fibrillary Acidic Protein / metabolism
  • Mesencephalon / drug effects
  • Mesencephalon / enzymology
  • Mesencephalon / pathology
  • Microglia / drug effects
  • Microglia / metabolism
  • Neuroprotective Agents / pharmacology*
  • Nitric Oxide Synthase Type I / antagonists & inhibitors*
  • Nitric Oxide Synthase Type I / metabolism
  • Nitric Oxide Synthase Type II / antagonists & inhibitors*
  • Nitric Oxide Synthase Type II / metabolism
  • Parkinson Disease / drug therapy
  • Parkinson Disease / enzymology
  • Picolines / toxicity*
  • Primary Cell Culture
  • Rats, Wistar
  • Thiophenes / pharmacology
  • Tyrosine / analogs & derivatives
  • Tyrosine / metabolism
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Amidines
  • Antibodies, Monoclonal
  • Benzylamines
  • Enzyme Inhibitors
  • Glial Fibrillary Acidic Protein
  • N-(3-(aminomethyl)benzyl)acetamidine
  • N-(4-(2-((3-chlorophenylmethyl)amino)ethyl)phenyl)-2-thiophenecarboxamide
  • Neuroprotective Agents
  • OX-6 monoclonal antibody
  • Picolines
  • Thiophenes
  • 3-nitrotyrosine
  • Tyrosine
  • Nitric Oxide Synthase Type I
  • Nitric Oxide Synthase Type II
  • Nos1 protein, rat
  • Nos2 protein, rat
  • Tyrosine 3-Monooxygenase
  • 4-methylpyridine